Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

PepGen Inc. - Common Stock (NQ: PEPG )

2.250 -0.220 (-8.91%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PepGen Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
From PepGen Inc.
Via Business Wire
PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls
PepGen halts its Phase 2 CONNECT2 trial for PGN-EDO51 in DMD to assess 10 mg/kg cohort data, while advancing FREEDOM-DM1 studies in myotonic dystrophy. 
Via Benzinga
PepGen to Participate in Upcoming Investor Conferences
From PepGen Inc.
Via Business Wire
PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD
From PepGen Inc.
Via Business Wire
What's Driving the Market Sentiment Around PepGen?
Via Benzinga
Why PepGen (PEPG) Stock Is Skyrocketing Today
PepGen shares are trading higher by 90% during Monday's session. The company announced early data from its FREEDOM-DM1 trial for myotonic dystrophy. 
Via Benzinga
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week
New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025. 
Via Stocktwits
These stocks have an unusual volume in today's session
Volume analysis on 2025-02-28: stocks with an unusual volume in today's session. 
Via Chartmill
PepGen Sees Fastest Weekly Retail Following Growth Among Biotech Stocks: What's Behind The Buzz?
The rally follows PepGen's release of early clinical data from its Phase 1 trial evaluating its therapy to treat a rare genetic disorder. 
Via Stocktwits
These stocks are moving in today's after hours session
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
Which stocks are experiencing notable movement on Thursday?
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. 
Via Chartmill
Which stocks are moving on Thursday?
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
Top movers in Monday's session
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
These stocks are making the most noise in today's session.
Let's dive into the action on the US markets on Monday. Here are the most active stocks that are driving the market today. 
Via Chartmill
These stocks are moving in today's session
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
There are notable gap-ups and gap-downs in today's session.
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via Business Wire
PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1
From PepGen Inc.
Via Business Wire
PepGen Announces CONNECT Program Updates
From PepGen Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy
From PepGen Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development
From PepGen Inc.
Via Business Wire
Roku To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via Business Wire
PepGen to Participate in Upcoming Investor Conferences
From PepGen Inc.
Via Business Wire
PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society
From PepGen Inc.
Via Business Wire
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathy 
Via MarketBeat
Exposures Product Safety
PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors
From PepGen Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.